CD26 as a target against fibrous formation in chronic airway rejection lesions.

[1]  P. Low,et al.  Reprogramming of profibrotic macrophages for treatment of bleomycin‐induced pulmonary fibrosis , 2020, EMBO molecular medicine.

[2]  F. Laenger,et al.  When tissue is the issue: A histological review of chronic lung allograft dysfunction , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  H. Lan,et al.  Macrophages: versatile players in renal inflammation and fibrosis , 2019, Nature Reviews Nephrology.

[4]  L. Pereira de Almeida,et al.  Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice. , 2018, Biochimica et biophysica acta. General subjects.

[5]  W. Xie,et al.  Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats , 2018, BioMed research international.

[6]  Yoshio Kobayashi,et al.  The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure. , 2017, Journal of pharmacological sciences.

[7]  K. Seung,et al.  Dipeptidyl peptidase 4 inhibitor attenuates obesity-induced myocardial fibrosis by inhibiting transforming growth factor-βl and Smad2/3 pathways in high-fat diet-induced obesity rat model. , 2017, Metabolism: clinical and experimental.

[8]  K. Tatsumi,et al.  Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition , 2017, Respiratory Research.

[9]  D. Kenkel,et al.  Chronic Airway Fibrosis in Orthotopic Mouse Lung Transplantation Models—An Experimental Reappraisal , 2017, Transplantation.

[10]  D. Hart,et al.  Elevated CD26 Expression by Skin Fibroblasts Distinguishes a Profibrotic Phenotype Involved in Scar Formation Compared to Gingival Fibroblasts. , 2017, The American journal of pathology.

[11]  J. Vincent,et al.  T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase‐9 via a C‐C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft Dysfunction , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  G. McCaughan,et al.  The pro‐fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride‐induced experimental liver injury , 2017, Immunology and cell biology.

[13]  D. Adriaensen,et al.  The expression of proline-specific enzymes in the human lung. , 2017, Annals of translational medicine.

[14]  I. De Meester,et al.  Anti‐inflammatory effects on ischemia/reperfusion‐injured lung transplants by the cluster of differentiation 26/dipeptidylpeptidase 4 (CD26/DPP4) inhibitor vildagliptin , 2017, The Journal of thoracic and cardiovascular surgery.

[15]  Y. Sakurai,et al.  Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis , 2017, Renal failure.

[16]  P. Pouwels,et al.  Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial , 2016, Diabetologia.

[17]  I. Yoshino,et al.  CD26 costimulatory blockade improves lung allograft rejection and is associated with enhanced interleukin-10 expression. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  T. Maher,et al.  Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease? , 2016, Trends in molecular medicine.

[19]  Aaron M. Newman,et al.  Identification and isolation of a dermal lineage with intrinsic fibrogenic potential , 2015, Science.

[20]  T. Aune,et al.  Regulation of Pulmonary Graft-versus-Host Disease by IL-26+CD26+CD4 T Lymphocytes , 2015, The Journal of Immunology.

[21]  O. Eickelberg,et al.  Tissue remodelling in chronic bronchial diseases: from the epithelial to mesenchymal phenotype , 2014, European Respiratory Review.

[22]  H. Yoshiji,et al.  Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats , 2014, Journal of Gastroenterology.

[23]  G. Verleden,et al.  A new classification system for chronic lung allograft dysfunction. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[24]  G. Opelz,et al.  The collaborative transplant study registry. , 2013, Transplantation reviews.

[25]  S. Keshavjee,et al.  Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis , 2013, Modern Pathology.

[26]  M. Sato.  Chronic lung allograft dysfunction after lung transplantation: the moving target , 2013, General Thoracic and Cardiovascular Surgery.

[27]  W. Weder,et al.  The Technique of Orthotopic Mouse Lung Transplantation as a Movie—Improved Learning by Visualization , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  G. Verleden,et al.  Chronic Rejection Pathology after Orthotopic Lung Transplantation in Mice: The Development of a Murine BOS Model and Its Drawbacks , 2012, PloS one.

[29]  W. Tourtellotte,et al.  Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. , 2011, Matrix biology : journal of the International Society for Matrix Biology.

[30]  Gerald N. Smith,et al.  Endogenous matrix metalloproteinases 2 and 9 regulate activation of CD4+ and CD8+ T cells. , 2011, American journal of respiratory cell and molecular biology.

[31]  S. Korom,et al.  A mouse model of orthotopic, single-lung transplantation. , 2009, The Journal of thoracic and cardiovascular surgery.

[32]  M. Fishbein,et al.  Chronic lung allograft rejection: mechanisms and therapy. , 2009, Proceedings of the American Thoracic Society.

[33]  H. Gollnick,et al.  Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. , 2008, The Journal of investigative dermatology.

[34]  K. Brune,et al.  Regulation of IL‐13 synthesis in human lymphocytes: implications for asthma therapy , 2002, British journal of pharmacology.

[35]  D. Marguet,et al.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. J. López,et al.  Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level. , 1999, Mediators of inflammation.